A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults

Ruth A. Karron, Karen Callahan, Catherine Luke, Bhagvanji Thumar, Josephine McAuliffe, Elizabeth Schappell, Tomy Joseph, Kathleen Coelingh, Hong Jin, George Kemble, Brian R. Murphy, Kanta Subbarao

Research output: Contribution to journalArticle

Abstract

Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 107-TCID50 doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had ≥4-fold increases in hemagglutination- inhibition antibody, and 79% had ≥4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults.

Original languageEnglish (US)
Pages (from-to)711-716
Number of pages6
JournalJournal of Infectious Diseases
Volume199
Issue number5
DOIs
StatePublished - Mar 1 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults'. Together they form a unique fingerprint.

  • Cite this

    Karron, R. A., Callahan, K., Luke, C., Thumar, B., McAuliffe, J., Schappell, E., Joseph, T., Coelingh, K., Jin, H., Kemble, G., Murphy, B. R., & Subbarao, K. (2009). A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. Journal of Infectious Diseases, 199(5), 711-716. https://doi.org/10.1086/596558